BMY Rallies as Q1 Earnings Beat and Upbeat Guidance Signal Growth Momentum
Bristol Myers Squibb (BMY) shares jumped 3.11% on Thursday after the pharmaceutical giant reported first-quarter earnings and revenue that comfortably cleared Wall Street estimates. The rally comes as the company signaled its full-year 2026 performance is trending toward the upper end of its guidance range, providing a sharp contrast to a nearly flat S&P 500.
Earnings Beat Driven by Growth Portfolio
Bristol Myers Squibb (BMY) delivered a robust first-quarter performance, reporting adjusted earnings of $1.58 per share, significantly outperforming the consensus analyst estimate of $1.42. Revenue for the period reached $11.49 billion, a 3% year-over-year increase that surpassed the $10.9 billion expected by the market.
The primary driver behind the outperformance was the company's "Growth Portfolio," which saw revenues climb 12% to $6.2 billion. This segment now accounts for more than half of the company's total revenue, a critical milestone as Bristol Myers works to offset the impact of patent expirations in its legacy business. Key contributors included the blood thinner Eliquis, which generated $4.14 billion in sales (up 16%), and newer treatments like Camzyos, which nearly doubled its revenue to $314 million. The cell therapy Breyanzi also showed significant strength, with sales surging 56% to $411 million.
Strategic Transition and Guidance Optimism
Investors reacted favorably to management's commentary regarding the remainder of the year. While the company officially reaffirmed its full-year 2026 guidance—forecasting revenue between $46.0 billion and $47.5 billion and non-GAAP EPS of $6.05 to $6.35—executives noted that results are currently trending toward the upper end of those ranges.
This optimism is rooted in the successful transition away from "Legacy Portfolio" products like the blood cancer treatment Revlimid, which saw sales plummet 63% to $349 million due to deepening generic competition. By successfully scaling its newer oncology, hematology, and cardiovascular assets, Bristol Myers is demonstrating its ability to navigate a challenging patent cliff that has historically weighed on its valuation.
Market Context and Analyst Sentiment
The stock's $59.38 price level represents a sharp divergence from the broader market, with BMY gaining over 3% while the SPY remained essentially flat at -0.04%. This relative strength highlights a rotation into value-oriented healthcare names that can provide clear earnings visibility.
Analysts noted that while some growth drivers like the cancer drug Opdivo showed mixed results due to inventory adjustments, the overall trajectory remains positive. RBC Capital Markets analyst Trung Huynh pointed toward the second half of 2026 as a period of even greater potential, citing upcoming data readouts for milvexian in atrial fibrillation and Cobenfy in Alzheimer's agitation. CEO Chris Boerner also highlighted the company's use of artificial intelligence to accelerate R&D, aiming to cut clinical development cycles by 30% over time, further bolstering the long-term efficiency narrative.
Key Takeaways
- BMY beat Q1 adjusted EPS estimates by $0.16, reporting $1.58 per share on $11.49 billion in revenue.
- The 'Growth Portfolio' now represents over 50% of total revenue, led by double-digit gains in Eliquis and Breyanzi.
- Management signaled that full-year 2026 revenue and earnings are tracking toward the high end of previous guidance.
- The stock sharply outperformed the S&P 500, gaining 3.11% in a session where the broader market was flat.